Recursion Pharmaceuticals, Inc. RXRX Lease liabilities
Lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept rxrx:IncreaseDecreaseInLeaseLiability.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s lease liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported lease liabilities of -$4.65M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s lease liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s lease liabilities increased by 19.2% year-over-year, from -$5.76M to -$4.65M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s lease liabilities?
- Over 2 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s lease liabilities has grown at a 67.7% compound annual growth rate (CAGR), from -$7.11M to -$19.99M.
- What does lease liabilities mean?
- Represents the net change in lease-related liabilities, reflecting the cash impact of lease payments versus the recognition of lease obligations. It serves as a measure of the company's ongoing commitment to leased infrastructure and its impact on operating cash flow.